Table 3 Items included in the questionnaire about “Olive and grass pollen allergy” (3A) and results (3B)
3A) | 3B) | ||||
|---|---|---|---|---|---|
Items | Mean | Median | % Panellists | IQ | Result |
Epidemiology | |||||
51- All olive-grass cosensitised patients are equal if they are from the same geographic area | 2.15 | 2 | 9.68 | 2 | D |
52- All olive-grass cosensitised patients are equal if they have the same size wheals | 1.84 | 1 | 4.84 | 1.5 | D |
53- The genuine sensitisation components (Phl p 1–5 and Ole e 1) are suitable for identifying phenotypes | 7.1 | 7 | 11.29 | 1 | A |
Clinical relevance | |||||
54- Geographic and aerobiological data are very important in identifying the clinical relevance of olive and grass cosensitised patients | 7.29 | 7 | 11.29 | 1 | A |
55- In olive-grass cosensitised patients, skin-tests have major limitations in confirming the clinical relevance | 7.18 | 7.5 | 16.13 | 1 | A |
56- A higher level of olive IgE than grass (or vice versa) is useful to highlight the clinical relevance in cosensitised patients | 4.08 | 3 | 45 | 2 | NC |
57- Confirmation of true sensitisation to olive or grass requires an IgE against genuine components | 7.56 | 8 | 8.06 | 1 | A |
58- The clinical relevance in olive-grass cosensitised patients can only be defined by organ-specific provocation tests | 3.19 | 3 | 25.81 | 2 | D |
Therapeutic strategy (Immunotherapy indication) | |||||
59- The identification of the relevant allergenic source in patients cosensitised to grass and olive is essential before prescribing immunotherapy | 7.98 | 8 | 4.84 | 1 | A |
60- The demonstrated efficacy in grass immunotherapy is the same as 50% mixture with olive | 2.92 | 3 | 20 | 1 | D |
61- In the case of olive-grass cosensitised patients, it is preferable to formulate personalised mixes (variable percentages of the two extracts) | 4.52 | 5 | 71.67 | 4 | NC |
62- As grass and olive are complex extracts, the dosage of individual allergens in immunotherapy would be appropriate | 7.05 | 7 | 10 | 1 | A |
63- The olive-grass cosensitised patient should not receive immunotherapy until more efficacy data is obtained | 2.55 | 2 | 14.52 | 2 | D |
Therapeutic strategy (Immunotherapy formulation) | |||||
64- The lack of knowledge of therapeutic doses makes the formulation of mixtures difficult | 6.82 | 7 | 27.42 | 2 | A |
65- It is correct to formulate olive-grass personalised mixes depending on the size of the wheal | 2.53 | 2 | 22.58 | 2 | D |
66- It is preferable to formulate olive-grass personalised mixes (varying percentages of the two extracts) in proportion to the IgE amount corresponding to the two extracts | 3.72 | 3 | 46.67 | 3.5 | NC |
67- If the manufacturer guarantees the individual doses of allergens, mixtures of different Poaceae and olive varieties are irrelevant | 6.95 | 7 | 23.33 | 1 | A |
68- Grass and olive personalised mixtures (varying percentages of the two extracts) should never be used | 3.92 | 3 | 30 | 2 | D |